3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
3
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
18
Lymphoma, Follicular
8
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Mantle-Cell
4
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, B-Cell
3
Neoplasms
2
Leukemia
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Mesothelioma
1
Melanoma
1
Mature B-Cell Malignancies
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Hairy Cell
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma Of Esophagus
1
Interventions
venetoclax
4
ibrutinib
4
obinutuzumab
3
fludarabine phosphate
3
fludarabine
3
Mesna
3
Cyclophosphamide
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Melphalan
2
Busulfan
2
zanubrutinib
1
ricolinostat
1
idelalisib
1
acalabrutinib
1
Bone Marrow Transplantation
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, B-Cell
×
obinutuzumab
×
Clear all
NCT04608318
2026-04-30
CLL17
German CLL Study Group
Phase 3
Active not recruiting
897 enrolled
NCT04515238
2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2
Active not recruiting
42 enrolled
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA